{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:50:25Z","timestamp":1790707825417,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.idc.2009.04.010","type":"journal-article","created":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T09:53:10Z","timestamp":1249638790000},"page":"665-681","source":"Crossref","is-referenced-by-count":12,"title":["New Antimicrobial Agents for Use in the Intensive Care Unit"],"prefix":"10.1016","volume":"23","author":[{"given":"David J.","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan T.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Finnegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2009.04.010_bib1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1378\/chest.115.2.462","article-title":"Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients","volume":"115","author":"Kollef","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.idc.2009.04.010_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","article-title":"The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting","volume":"118","author":"Ibrahim","year":"2000","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.idc.2009.04.010_bib3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2009.04.010_bib4","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/01.CCM.0000227655.41566.3E","article-title":"Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment","volume":"34","author":"Schramm","year":"2006","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.idc.2009.04.010_bib5","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.00851-07","article-title":"Health care-associated pneumonia and community-acquired pneumonia: a single-center experience","volume":"51","author":"Micek","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2009.04.010_bib6","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to imitation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.04.010_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2009.04.010_bib9","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jac\/dkm150","article-title":"In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes","volume":"60","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2009.04.010_bib11","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States","volume":"52","author":"Ge","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-004-0309-3","article-title":"In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAL-599","volume":"10","author":"Iizawa","year":"2004","journal-title":"J Infect Chemother"},{"issue":"11","key":"10.1016\/j.idc.2009.04.010_bib13","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1128\/AAC.00712-08","article-title":"In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime","volume":"52","author":"Fenoll","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.04.010_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.01324-08","article-title":"In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae","volume":"53","author":"McGee","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib15","unstructured":"Ge Y, Redman R, Floren L, et al. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. (abstract A-1937). In: abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27\u201330, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib16","unstructured":"Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903). (abstract A-1935). In: abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27\u201330, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib17","unstructured":"Ge Y, Liao S, Talbot GH. Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infection (cSSSI). (abstract A-34). In: abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17\u201320, 2007."},{"key":"10.1016\/j.idc.2009.04.010_bib18","unstructured":"Ge Y, Thye D, Liao S, et al. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI). (abstract A-1939). In: abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27\u201330, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib19","unstructured":"Ge Y, Floren L, Redman R, et al. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. (abstract A-1936). In: abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27\u201330, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib20","unstructured":"Jacqueline C, Caillon J, Miegeville A, et al. Penetration of ceftaroline (PPI-0903), a newcephalosporin, into lung tissues: measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit. (abstract A-1938). In: abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27\u201330, 2006."},{"issue":"10","key":"10.1016\/j.idc.2009.04.010_bib21","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in the treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib22","unstructured":"Available at: http:\/\/www.clinicaltrials.gov\/ct2\/results?term=ceftaroline. Accessed February 2, 2009."},{"key":"10.1016\/j.idc.2009.04.010_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY antimicrobial surveillance program (2005-2006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2009.04.010_bib24","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00336-08","article-title":"In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections","volume":"52","author":"Amsler","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib25","unstructured":"Amsler K, Jacobs M, Sahm D, et al. Ceftobiprole activity against baseline pathogens from recent pneumonia trials. (abstract C1-159). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"issue":"3","key":"10.1016\/j.idc.2009.04.010_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.45.3.825-836.2001","article-title":"In vitro and in vivo properties of Ro-63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci","volume":"45","author":"Hebeisen","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2009.04.010_bib27","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1128\/AAC.00218-07","article-title":"Interactions of ceftobiprole with \u00df-lactamases from molecular classes A to D","volume":"51","author":"Queenan","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 2","key":"10.1016\/j.idc.2009.04.010_bib28","doi-asserted-by":"crossref","first-page":"ii41","DOI":"10.1093\/jac\/dkn351","article-title":"Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06","volume":"62","author":"Livermore","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 2","key":"10.1016\/j.idc.2009.04.010_bib29","article-title":"Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06","volume":"62","author":"Livermore","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.04.010_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003088-200847010-00003","article-title":"Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity","volume":"47","author":"Murthy","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.idc.2009.04.010_bib31","unstructured":"Kimko H, Murthy B, Balis D, et al. Pharmacokinetics of ceftobiprole (BPR) in patients with ventilator-associated pneumonia (VAP). (abstract A-1881). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"key":"10.1016\/j.idc.2009.04.010_bib32","unstructured":"Available at: http:\/\/www.clinicaltrials.gov\/ct2\/results?term=ceftobiprole. Acces-sed February 2, 2009."},{"key":"10.1016\/j.idc.2009.04.010_bib33","doi-asserted-by":"crossref","unstructured":"Schmitt-Hoffmann, Roos B, Schleimer M, A et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48(7):2570\u20135.","DOI":"10.1128\/AAC.48.7.2570-2575.2004"},{"issue":"7","key":"10.1016\/j.idc.2009.04.010_bib34","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1128\/AAC.48.7.2576-2580.2004","article-title":"Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers","volume":"48","author":"Schmitt-Hoffmann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2009.04.010_bib35","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/AAC.01181-06","article-title":"Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib36","unstructured":"Murthy B, Skee D, Vaccaro N, et al. An open-label pharmacokinetic study of ceftobiprole in healthy subjects and subjects with end-stage renal disease receiving hemodialysis. (abstract A-1896). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"issue":"1","key":"10.1016\/j.idc.2009.04.010_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib38","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.04.010_bib39","unstructured":"Noel GJ, Strauss RS, Shah A, et al. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. (abstract K-486). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"key":"10.1016\/j.idc.2009.04.010_bib40","unstructured":"Baum EZ, Crespo-Carbone SM, Foleno BD, et al. MexXY expression in Pseudomonas aeruginosa (PsA) and susceptibility to cephalosporins, including ceftobiprole. (abstract C1-158). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"key":"10.1016\/j.idc.2009.04.010_bib41","unstructured":"Queenan AM, Shang W, Crespo-Carbone S, et al. Mechanisms of ceftobiprole and ceftazidime resistance development in gram-negative clinical isolates from cSSSI subjects. (abstract C1-154). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"issue":"1","key":"10.1016\/j.idc.2009.04.010_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/14787210.6.1.67","article-title":"Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of gram-positive infections","volume":"6","author":"Zhanel","year":"2008","journal-title":"Expert Rev Ant Infect Ther"},{"issue":"9","key":"10.1016\/j.idc.2009.04.010_bib43","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003495-200464090-00001","article-title":"Glycopeptide antibiotics from conventional molecules to new derivatives","volume":"64","author":"Van Bambeke","year":"2004","journal-title":"Drugs"},{"issue":"suppl S2","key":"10.1016\/j.idc.2009.04.010_bib44","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/44.2.179","article-title":"In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic","volume":"44","author":"Candiani","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2009.04.010_bib46","first-page":"740","article-title":"Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics, and clinical efficacy","volume":"7","author":"Van Bambeke","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.idc.2009.04.010_bib47","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.00620-06","article-title":"Bactericidal activity and resistance development profiling of dalbavancin","volume":"51","author":"Goldstein","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2009.04.010_bib48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: a novel antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.idc.2009.04.010_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1345\/aph.1G158","article-title":"Dalbavancin: a new option for the treatment of gram-positive infections","volume":"40","author":"Lin","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.idc.2009.04.010_bib50","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.04.010_bib51","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.04.010_bib52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.04.010_bib53","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib54","unstructured":"Available at: http:\/\/mediaroom.pfizer.com\/news\/pfizer\/20080909005943\/en. Accessed January 6, 2009."},{"issue":"3","key":"10.1016\/j.idc.2009.04.010_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/14787210.3.3.325","article-title":"Oritavancin: a new avenue for resistant gram-positive bacteria","volume":"3","author":"Mercier","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"10.1016\/j.idc.2009.04.010_bib56","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/JCM.36.4.1020-1027.1998","article-title":"Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides","volume":"36","author":"Tenover","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idc.2009.04.010_bib57","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1016\/j.bmcl.2003.08.067","article-title":"Semi-synthetic glycopeptide antibacterials","volume":"13","author":"Judice","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.idc.2009.04.010_bib58","unstructured":"Lehoux D, McKay G, Fadhil I, et al. Efficacy of oritavancinin a mouse model of Streptococcus pneumoniae pneumonia. (abstract P1781). In: Program and abstracts of the European Society of Clinical Microbiology and Infectious Diseases 25th ICC. Munich: March 31\u2013April 3, 2007."},{"key":"10.1016\/j.idc.2009.04.010_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.06.007","article-title":"Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects","volume":"50","author":"Bhavnani","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2009.04.010_bib60","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.49.5.1695-1700.2005","article-title":"Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation","volume":"49","author":"Van Bambeke","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib61","unstructured":"A study for patients with complicated skin and skin structure infections (SIMPLIFI). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00514527?term=oritavancin&rank=1. Accessed February 1, 2009."},{"issue":"issue s3","key":"10.1016\/j.idc.2009.04.010_bib62","first-page":"122","article-title":"Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteraemia. (abstract P541)","volume":"10","author":"Loutit","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2009.04.010_bib63","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.42.4.981","article-title":"Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis","volume":"42","author":"Kaatz","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2009.04.010_bib64","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/AAC.44.11.3017-3021.2000","article-title":"Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis","volume":"44","author":"Lefort","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2009.04.010_bib65","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1128\/AAC.45.7.2169-2172.2001","article-title":"Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin","volume":"45","author":"Gerber","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.04.010_bib66","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.47.6.1907-1911.2003","article-title":"Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis","volume":"47","author":"Cabellos","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib67","unstructured":"Available at: http:\/\/www.investorcalendar.com\/IC\/GenRelease.asp?ID=138672. Accessed February 1, 2009."},{"issue":"4","key":"10.1016\/j.idc.2009.04.010_bib68","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1592\/phco.28.4.458","article-title":"Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections","volume":"28","author":"Leonard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2009.04.010_bib69","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2146\/ajhp070080","article-title":"Telavancin: a novel lipoglycopeptide antimicrobial agent","volume":"64","author":"Attwood","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.idc.2009.04.010_bib70","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dkh156","article-title":"Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria","volume":"53","author":"King","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jac\/dki198","article-title":"Telavancin: in vitro activity against staphylococci in a biofilm model","volume":"56","author":"Gander","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib72","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkl235","article-title":"Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Leuthner","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.04.010_bib73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/TCRM.S1843","article-title":"A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)","volume":"4","author":"Dunbar","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.idc.2009.04.010_bib74","unstructured":"Available at: http:\/\/ir.theravance.com\/ReleaseDetail.cfm?ReleaseID=279919. Accessed January 6, 2009."},{"key":"10.1016\/j.idc.2009.04.010_bib75","unstructured":"Available at: http:\/\/ir.theravance.com\/ReleaseDetail.cfm?ReleaseID=348983. Accessed January 24, 2009."},{"key":"10.1016\/j.idc.2009.04.010_bib76","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.bmcl.2003.07.023","article-title":"Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria","volume":"13","author":"Schneider","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.idc.2009.04.010_bib77","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bcp.2005.10.052","article-title":"Dihydrofolate reductase inhibitors as antibacterial agents","volume":"71","author":"Hawser","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.idc.2009.04.010_bib78","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/jac\/dkm409","article-title":"In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action","volume":"60","author":"Laue","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib79","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical center","volume":"52","author":"Bozdogan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib80","unstructured":"Mason E, Lamberth L, Hawser S, et al. In-vitro activity of iclaprim against community-acquired and nosocomial clinical isolates of Staphylococcus aureus (abstract E-904). In: abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17\u201320, 2007."},{"key":"10.1016\/j.idc.2009.04.010_bib81","unstructured":"Sader HS, Jones RN, Rhomberg P, et al. Comparativeevaluation of iclaprim potency and bactericidal activity tested against enterococci; results from the International Study of Iclaprim Susceptibility (ISIS) (abstract E-910). In: abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17\u201320, 2007."},{"key":"10.1016\/j.idc.2009.04.010_bib82","unstructured":"Jones RN, Fritsche TR, Hawser S, et al. In vitro activityof iclaprim, a novel diaminopyrimidine, tested against \u00df-hemolytic streptococci from the USA and Europe: results from the International Study of Iclaprim Susceptibility (ISIS) (abstract E-911). In: abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17\u201320, 2007."},{"key":"10.1016\/j.idc.2009.04.010_bib83","unstructured":"Hawser S, Lociuro S, Islam K. In vitro spectrum of activity of iclaprim against various Gram-positive and Gram-negative pathogens (poster CPLA-32). Presented at: The third International Symposium on Resistant Gram-positive Infections. Niagara-on-the-Lake, Ontario: October 9\u201311, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib84","unstructured":"Jones RN, Fritsche TR, Islam K, et al. Antimicrobial activity of a novel dihydrofolate reductase, iclaprim, tested against clinical strains of Enterobacteriaceae: results from the International Study of Iclaprim Susceptibility (ISIS) (abstract E-909). In: abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17\u201320, 2007."},{"issue":"5","key":"10.1016\/j.idc.2009.04.010_bib85","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1128\/AAC.48.5.1885-1886.2004","article-title":"In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae","volume":"48","author":"Kohlhoff","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib86","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jac\/dkm288","article-title":"Activity of iclaprim against Legionella pneumophila","volume":"60","author":"Morrissey","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib87","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/525536","article-title":"Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Proctor","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2009.04.010_bib88","unstructured":"Haldimann A, Hawser S, Bihr M, et al. Effectof thymidine on the activity of diaminopyrimidine antibacterial agents: generation and characterization of thymidine kinase-deficient Staphylococcus aureus mutants (abstract C1-940). In: abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27\u201330, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib89","unstructured":"Food and Drug Administration (FDA). FDA briefing document for Anti-infective Drugs Advisory Committee Meeting, November 20, 2008 (Iclaprim for the treatment of complicated skin and skin structure infection). Available at: http:\/\/fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4394b3-01-FDA.pdf. Accessed December 23, 2008."},{"key":"10.1016\/j.idc.2009.04.010_bib90","unstructured":"Brandt R, Neuenhofer D, Thomsen T, et al. Pharmacokinetics and bioavailability of iclaprim oral and intravenous formulations in humans. (abstract A-806). In: abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17\u201320, 2007."},{"key":"10.1016\/j.idc.2009.04.010_bib91","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jac\/dkm242","article-title":"Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg\/kg of iclaprim (AR-100) in healthy men","volume":"60","author":"Andrews","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib92","unstructured":"Hadvary P, de la Motte S, Klinger J, et al. Pharmacokinetics of iclaprim in subjects with varying degree of hepatic or renal insufficiency or obesity. (poster 448). In: abstracts of the 45th Annual Meeting of the Infectious Diseases Society of America. San Diego: October 4\u20137, 2007."},{"key":"10.1016\/j.idc.2009.04.010_bib93","unstructured":"Hadvary P, Stevens D, Solonets M, et al. Clinical efficacy of iclaprim in complicated skin and skin structure infection (cSSSI): results of combined ASSIST phase III studies. (abstract L-1512). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"key":"10.1016\/j.idc.2009.04.010_bib94","unstructured":"Clinical efficacy of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associated pneumonia. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00543608?term=iclaprim&rank=1. Accessed January 2, 2009."},{"key":"10.1016\/j.idc.2009.04.010_bib95","unstructured":"Available at: http:\/\/www.clinicaltrials.gov\/ct2\/results?term=isavuconazole. Accessed January 2, 2009."},{"issue":"5","key":"10.1016\/j.idc.2009.04.010_bib96","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1128\/AAC.01217-06","article-title":"In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates","volume":"51","author":"Seifert","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.04.010_bib97","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib98","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/dki399","article-title":"In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp","volume":"57","author":"Warn","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.04.010_bib99","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.01384-07","article-title":"In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba","volume":"52","author":"Illnait-Zaragozi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib100","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jac\/dkn076","article-title":"Activity of BAL 4815 against filamentous fungi","volume":"61","author":"Martin de la Escalera","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.04.010_bib101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13693780802562969","article-title":"In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi","volume":"47","author":"Gonzalez","year":"2009","journal-title":"Med Mycol"},{"key":"10.1016\/j.idc.2009.04.010_bib102","unstructured":"Perkhofer S, Lechner V, Lass-Florl C. The in vitro activity of isavuconazole against Aspergillus species and zygomycetes according to EUCAST methodology (abstract M-1526). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"issue":"1","key":"10.1016\/j.idc.2009.04.010_bib103","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.04.010_bib104","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib105","unstructured":"Schmitt-Hoffmann A, Roos B, Roehrle M, et al. No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data (abstract A-008). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"key":"10.1016\/j.idc.2009.04.010_bib106","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0960-894X(02)00892-2","article-title":"Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole","volume":"13","author":"Ohwada","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.idc.2009.04.010_bib107","unstructured":"Schmitt-Hoffmann A, Roos B, Peterfai E, et al. Pharmacokinetics of isavuconazole in liver impairment. Preliminary data. (abstract A-007). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"key":"10.1016\/j.idc.2009.04.010_bib108","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/jac\/dkl396","article-title":"Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus","volume":"58","author":"Warn","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib109","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/dkn431","article-title":"Efficacy of isavuconazole, voriconazole, and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei","volume":"63","author":"Majithiya","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.04.010_bib110","unstructured":"Viljoen JJ, Mitha I, Heep M, et al. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs. fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised hosts (abstract LB2-32). In: abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: December 16\u201319, 2005."},{"key":"10.1016\/j.idc.2009.04.010_bib111","unstructured":"Cornely OA, Bohme A, Reichert D, et al. Pharmacokinetics, safety, and tolerability results from a dose-escalation study of isavuconazole in neutropenic patients (abstract M-2137). In: abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25\u201328, 2008."},{"key":"10.1016\/j.idc.2009.04.010_bib112","unstructured":"Schmitt-Hoffmann A, Roos B, Sauer J, et al. Effect of BAL8557, a water-soluble azole pro-drug, on the pharmacokinetics of ciclosporin (abstract P-0136). In: abstracts of The 16th Congress of the International Society for Human and Animal Mycology. Paris: June 26\u201329, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib113","unstructured":"Schmitt-Hoffmann A, Roos B, Sauer J, et al. Effectof BAL8557, a water-soluble azole pro-drug, on the pharmacokinetics of tacrolimus. (abstract P-0320). In: abstracts of The 16th Congress of the International Society for Human and Animal Mycology. Paris: June 26\u201329, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib114","unstructured":"Schmitt-Hoffmann A, Roos B, Sauer J, et al. Effect of BAL8557, a water-soluble azole pro-drug, on the pharmacokinetics of S- and R-warfarin (abstract P-0321). In: abstracts of The 16th Congress of the International Society for Human and Animal Mycology. Paris: June 26\u201329, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib115","unstructured":"Schmitt-Hoffmann A, Roos B, Sauer J, et al. Effectof ketoconazole on the pharmacokinetics of BAL4815 at steady state after multiple oral daily doses of BAL8557 (WSA) and ketoconazole (abstract P-0318). In: abstracts of The 16th Congress of the International Society for Human and Animal Mycology. Paris: June 26\u201329, 2006."},{"key":"10.1016\/j.idc.2009.04.010_bib116","unstructured":"Schmitt-Hoffmann A, Roos B, Sauer J, et al. Effectof rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral daily doses of BAL8557 and rifampicin. (abstract P-0319). In: abstracts of The 16th Congress of the International Society for Human and Animal Mycology. Paris: June 26\u201329, 2006."},{"issue":"suppl. 1","key":"10.1016\/j.idc.2009.04.010_bib117","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/jac\/dkm428","article-title":"New and emerging treatments for fungal infections","volume":"61","author":"Pasqualetto","year":"2008","journal-title":"J Antimicrob Chemother"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552009000397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552009000397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T08:12:52Z","timestamp":1590048772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552009000397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":117,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0891552009000397"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2009.04.010","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}